Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Baxter
Express Scripts
Medtronic
Johnson and Johnson

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMATINIB MESYLATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for imatinib mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed Medical Research Council Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed National Cancer Institute (NCI) Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed Eastern Cooperative Oncology Group Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00004932 ↗ STI571 in Treating Patients With Recurrent Leukemia Completed National Cancer Institute (NCI) Phase 1 2002-01-01 RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for imatinib mesylate

Condition Name

Condition Name for imatinib mesylate
Intervention Trials
Leukemia 52
Gastrointestinal Stromal Tumor 22
Chronic Myeloid Leukemia 16
Chronic Myelogenous Leukemia 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for imatinib mesylate
Intervention Trials
Leukemia 127
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 96
Leukemia, Myeloid 95
Gastrointestinal Stromal Tumors 50
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for imatinib mesylate

Trials by Country

Trials by Country for imatinib mesylate
Location Trials
United States 905
Canada 70
Australia 53
United Kingdom 42
Italy 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for imatinib mesylate
Location Trials
Texas 77
California 62
New York 52
Illinois 42
Pennsylvania 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for imatinib mesylate

Clinical Trial Phase

Clinical Trial Phase for imatinib mesylate
Clinical Trial Phase Trials
Phase 4 7
Phase 3 29
Phase 2/Phase 3 5
[disabled in preview] 195
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for imatinib mesylate
Clinical Trial Phase Trials
Completed 221
Terminated 54
Unknown status 25
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for imatinib mesylate

Sponsor Name

Sponsor Name for imatinib mesylate
Sponsor Trials
National Cancer Institute (NCI) 108
Novartis Pharmaceuticals 46
M.D. Anderson Cancer Center 38
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for imatinib mesylate
Sponsor Trials
Other 318
Industry 158
NIH 110
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Mallinckrodt
McKesson
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.